Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 3/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | PTPRF | P10586 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2420985 | 0.85 | ACHE (0.42) | ACHECYP19A1HTR2CHTTPDE4A | |
| SCHEMBL2417918 | 0.85 | ACHE (0.42) | ACHECYP19A1HTR2C | |
| SCHEMBL28883602 | 0.77 | CYP19A1 (0.58) | ACHECYP19A1 | |
| SCHEMBL2423359 | 0.75 | CYP24A1 (0.31) | ACHECYP19A1 | |
| SCHEMBL5726327 | 0.74 | MAPK1 (0.33) | ACHE | |
| SCHEMBL2421175 | 0.74 | HTT (0.35) | ACHEPTPRFHTTPDE4APDE4B | |
| SCHEMBL5952753 | 0.73 | ACHE (0.34) | ACHECYP19A1HTR2CHTT | |
| SCHEMBL9343214 | 0.72 | CYP19A1 (0.61) | ACHECYP19A1HTR2C | |
| SCHEMBL4730233 | 0.71 | ACHE (0.43) | ACHECYP19A1HTR2C | |
| SCHEMBL2424817 | 0.71 | METAP1 (0.65) | ACHECYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1257264-B1 | ESTROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME (US) | 2011-09-14 | — | — | EP | disclosed |
| US-7087599-B2 | Estrogen receptor modulators | MERCK & CO., INC. (US) | 2006-08-08 | — | — | US | disclosed |
| EP-1257264-A4 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2005-08-10 | — | — | EP | disclosed |
| US-20050137192-A1 | Estrogen receptor modulators | PARKER DANN R JR (US) | 2005-06-23 | — | — | US | disclosed |
| US-20030027840-A1 | Estrogen receptor modulators | MERCK SHARP & DOHME LLC | 2003-02-06 | — | — | US | disclosed |
| EP-1257264-A1 | ESTROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2002-11-20 | — | — | EP | disclosed |
| WO-2001082923-A1 | ESTROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2001-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030027840-A1 | Estrogen receptor modulators | GPER1, ESR2, ESRRA | ACHE 293/4885CYP19A1 8/4885PTPRF 965/4885 |
| US-20050137192-A1 | Estrogen receptor modulators | GPER1, ESR2, ESRRA | ACHE 293/4885CYP19A1 8/4885PTPRF 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.